ADC (Antibody Drug Conjugates)

Antibody-drug conjugates (ADCs) are targeted immunotherapies that utilize potent cytotoxic drugs conjugated to antibodies via chemical linkers. This increases the efficacy of chemotherapeutic agents by effectively targeting the drug directly to cancer cells. Thus, ADCs also have reduced side effects because targeting the cancer cells means less of the cytotoxic drug will enter healthy cells.

Sorrento’s next generation ADC technology platform utilizes innovative conjugation methods to produce stable ADCs by linking the toxin to only specific, preselected sites of an antibody; the resulting ADCs have shown high anti-tumor efficacy in preclinical studies.

ADC technology uses proprietary conjugation chemistries (C-Lock™ and K-Lock™), initially developed by Concortis Biosystems, Corp.

The combination of C-Lock and K-Lock conjugation methods enables multifunctional ADCs, such as dual drug ADCs and Bispecific ADCs. We are also actively studying the combination of ADCs with immuno-oncology therapy as a new anti-cancer strategy.

We are developing ADCs targeting CD38 and BCMA.